Beta: Sign in
Shares outstandingAs of 2026-07-31 · filed common shares: 96.69M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.44%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 19.41%
Short ratioDays to cover, as published by FINRA: 10.73
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 59.20%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 60.20%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Profitability

Gross margin: —
Operating marginTTM to Jun 26: -3989.99%
Net margin: —
EBITDA marginTTM to Jun 26: -3850.41%
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -26.09%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -19.28%

Growth

Revenue growth (annual YoY): -90.59%
Revenue growth (latest qtr YoY): 1041.37%
Revenue growth (fwd): Sign in
Net income growth (annual YoY): —
Net income growth (latest qtr YoY): —
EPS growth (fwd): Sign in
Net income growth (QoQ): —

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Jun 26

-4.71

EPS (fwd)

Financial health

Cash & equivalentsas of Jun 26: $291.33M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $783.74M
Debt / equityas of Jun 26: 44.87%
Current ratioas of Jun 26: 17.85
Quick ratio(Cash + marketable securities + receivables) ÷ current liabilities, as of Dec 25: 13.25
Operating cash flowTTM to Jun 26: -$369.58M
Free cash flowUnadjusted FCF = CFO − capex · TTM to Jun 26: -$371.32M
TTM revenue / diluted shareDiluted, TTM to Jun 26: 0.14

CRSP stock Statistics — CRISPR Therapeutics AG filings, insiders & smart money · Instaport